Identification of a microRNA signature for the diagnosis of fibromyalgia.

Diagnosis of fibromyalgia (FM), a chronic musculoskeletal pain syndrome characterized by generalized body pain, hyperalgesia and other functional and emotional comorbidities, is a challenging process hindered by symptom heterogeneity and clinical overlap with other disorders. No objective diagnostic...

Full description

Bibliographic Details
Main Authors: Germán Cerdá-Olmedo, Armando Vicente Mena-Durán, Vicente Monsalve, Elisa Oltra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4372601?pdf=render
id doaj-be91b2c13f334e55abe478f6513faafd
record_format Article
spelling doaj-be91b2c13f334e55abe478f6513faafd2020-11-24T21:27:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e012190310.1371/journal.pone.0121903Identification of a microRNA signature for the diagnosis of fibromyalgia.Germán Cerdá-OlmedoArmando Vicente Mena-DuránVicente MonsalveElisa OltraDiagnosis of fibromyalgia (FM), a chronic musculoskeletal pain syndrome characterized by generalized body pain, hyperalgesia and other functional and emotional comorbidities, is a challenging process hindered by symptom heterogeneity and clinical overlap with other disorders. No objective diagnostic method exists at present. The aim of this study was to identify changes in miRNA expression profiles (miRNome) of these patients for the development of a quantitative diagnostic method of FM. In addition, knowledge of FM patient miRNomes should lead to a deeper understanding of the etiology and/or symptom severity of this complex disease.Genome-wide expression profiling of miRNAs was assessed in Peripheral Blood Mononuclear Cells (PBMCs) of FM patients (N=11) and population-age-matched controls (N=10) using human v16-miRbase 3D-Gene microarrays (Toray Industries, Japan). Selected miRNAs from the screen were further validated by RT-qPCR. Participating patients were long term sufferers (over 10 years) diagnosed by more than one specialist under 1990 American College of Rheumatology criteria.Microarray analysis of FM patient PBMCs evidenced a marked downregulation of hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p, hsa-miR145-5p and hsa-miR-21-5p (4-fold or more). All but the mildest inhibited miRNA, hsa-miR-21-5p, were validated by RT-qPCR. Globally, 20% of the miRNAs analyzed (233/1212) showed downregulation of at least 2-fold in patients. This might indicate a general de-regulation of the miRNA synthetic pathway in FM. No significant correlations between miRNA inhibition and FM cardinal symptoms could be identified. However, the patient with the lowest score for mental fatigue coincided with the mildest inhibition in four of the five miRNAs associated with the FM-group.We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.http://europepmc.org/articles/PMC4372601?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Germán Cerdá-Olmedo
Armando Vicente Mena-Durán
Vicente Monsalve
Elisa Oltra
spellingShingle Germán Cerdá-Olmedo
Armando Vicente Mena-Durán
Vicente Monsalve
Elisa Oltra
Identification of a microRNA signature for the diagnosis of fibromyalgia.
PLoS ONE
author_facet Germán Cerdá-Olmedo
Armando Vicente Mena-Durán
Vicente Monsalve
Elisa Oltra
author_sort Germán Cerdá-Olmedo
title Identification of a microRNA signature for the diagnosis of fibromyalgia.
title_short Identification of a microRNA signature for the diagnosis of fibromyalgia.
title_full Identification of a microRNA signature for the diagnosis of fibromyalgia.
title_fullStr Identification of a microRNA signature for the diagnosis of fibromyalgia.
title_full_unstemmed Identification of a microRNA signature for the diagnosis of fibromyalgia.
title_sort identification of a microrna signature for the diagnosis of fibromyalgia.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Diagnosis of fibromyalgia (FM), a chronic musculoskeletal pain syndrome characterized by generalized body pain, hyperalgesia and other functional and emotional comorbidities, is a challenging process hindered by symptom heterogeneity and clinical overlap with other disorders. No objective diagnostic method exists at present. The aim of this study was to identify changes in miRNA expression profiles (miRNome) of these patients for the development of a quantitative diagnostic method of FM. In addition, knowledge of FM patient miRNomes should lead to a deeper understanding of the etiology and/or symptom severity of this complex disease.Genome-wide expression profiling of miRNAs was assessed in Peripheral Blood Mononuclear Cells (PBMCs) of FM patients (N=11) and population-age-matched controls (N=10) using human v16-miRbase 3D-Gene microarrays (Toray Industries, Japan). Selected miRNAs from the screen were further validated by RT-qPCR. Participating patients were long term sufferers (over 10 years) diagnosed by more than one specialist under 1990 American College of Rheumatology criteria.Microarray analysis of FM patient PBMCs evidenced a marked downregulation of hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p, hsa-miR145-5p and hsa-miR-21-5p (4-fold or more). All but the mildest inhibited miRNA, hsa-miR-21-5p, were validated by RT-qPCR. Globally, 20% of the miRNAs analyzed (233/1212) showed downregulation of at least 2-fold in patients. This might indicate a general de-regulation of the miRNA synthetic pathway in FM. No significant correlations between miRNA inhibition and FM cardinal symptoms could be identified. However, the patient with the lowest score for mental fatigue coincided with the mildest inhibition in four of the five miRNAs associated with the FM-group.We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
url http://europepmc.org/articles/PMC4372601?pdf=render
work_keys_str_mv AT germancerdaolmedo identificationofamicrornasignatureforthediagnosisoffibromyalgia
AT armandovicentemenaduran identificationofamicrornasignatureforthediagnosisoffibromyalgia
AT vicentemonsalve identificationofamicrornasignatureforthediagnosisoffibromyalgia
AT elisaoltra identificationofamicrornasignatureforthediagnosisoffibromyalgia
_version_ 1725976271110799360